A recognized leader with highly successful experience and expertise in transforming and restructuring public and private companies, establishing strong governance processes and operational discipline, resulting in operational improvements, significant revenue and enterprise value growth.  During his career, he has overseen the approval of over 10 NDAs, over 15 acquisitions/divestitures, in excess of $2.5 billion in financial transactions and, led over $5 billion in incremental enterprise growth.

Key highlights of Mr. Dodd’s career include: 

• During Mr. Dodd’s six-year tenure as President, CEO and Director of Serologicals Corporation, he led a transformation of that Company during which the enterprise value increased over $1 billion…from $85 million to an all-cash sale to Millipore Corporation of $1.5 billion;
• Mr. Dodd served as President, CEO & Director of Solvay Pharmaceuticals, Inc., during which the enterprise value increased over $2 billion – from $100 million to $2.5 billion over a five-year period; 
• Mr. Dodd joined the GeoVax Board of Directors in March 2010 and was elected Chairman in January 2011.  Effective September 2018, he began serving also as the President, CEO.  Mr. Dodd has led the Company through a significant transformation from being focused on a single vaccine (HIV/AIDS) to developing an attractive portfolio of human vaccines in infectious diseases and cancer immunotherapy.   At the 2018 World Vaccine Congress, GeoVax received the “Best Biotech” recognition award, a reflection of the opinions of the vaccine industry public and private members.
• As President, CEO & Director of Aeterna Zentaris, Mr. Dodd led the development of and FDA approval of Macrilen™, the first and only product successfully developed and receiving regulatory approval in the 30+history of that company; 
• Mr. Dodd also served in executive roles with Wyeth-Ayerst Laboratories (now part of Pfizer), Bristol-Myers Squibb and Abbott Laboratories; 

He is a frequent invited speaker and panelist at business and economic development conferences, as well as various conferences focused on the life sciences and pharmaceutical industry.  Mr. Dodd is a recipient of the Oglethorpe Award for UK-US Business Relationships recognized by the British American Business Council, the Georgia BIO Industry Growth Award, and a multi-year recipient of the FastTech 50 Growth Company Award (2000-2006) while leading Serologicals Corporation.

In addition, he has served on a development committee of the MacArthur Foundation, as an advisor to the First Minister of Scotland, as the Chair of the American Foundation for Suicide Prevention, as a member of the External Advisory Board of the Petit Institute for Bioengineering & Biosciences (GaTech), as the Chair of GaBio, as a board member on the Harvard Business School Healthcare Alumni Association and, in leadership roles with numerous additional organizations.

Mr. Dodd holds Bachelor of Science and Master of Science degrees from Georgia State University and completed the Harvard Business School of Advanced Management Program.